In vivo models for endocrine-dependent breast carcinomas: Special considerations of clinical relevance

European Journal of Cancer

Volumn 40, Issue 6, 2004, Pages 845-851

  Fichtner, I ^a   Becker, M ^b   Zeisig, R ^a   Sommer, A ^c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b Exp Pharmacol Oncol Berlin B   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Anti oestrogen resistance; Breast carcinomas; Microarray studies; Oestrogen receptor; Tamoxifen

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ANTIESTROGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FULVESTRANT; HORMONE RECEPTOR; METHOTREXATE; MILTEFOSINE; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; VINCRISTINE;

BREAST CARCINOMA; CANCER RESEARCH; CHEMOSENSITIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SENSITIVITY; EXPERIMENTAL MOUSE; EXPERIMENTATION; GENE EXPRESSION; HUMAN; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; XENOGRAFT;

EID: 1942454412     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.030     Document Type: Article

References (22)

1. Winograd B., Boven E., Lobbezzo M.W., Pinedo H.M. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (Review). In vivo. 1:1987;1-14.
2. Widmaier R., Wildner G.P., Papsdorf G., Graffi I. A new infinite cell line, MaTu, of human mammary tumor-cells. Archiv für Geschwulstforschung. 44:1974;1-10.
3. Johnston S.R.D. Acquired tamoxifen resistance in human breast cancer - potential mechanisms and clinical implications. Anticancer Drugs. 8:1997;911-930.
4. Clark R., Leonessa F., Welch J.N., Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53:2001;25-71.
5. Naundorf H., Becker M., Lykkesfeldt A.E., Elbe B., Neumann C., Büttner B., Fichtner I. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Brit. J. Cancer. 82:2000;1844-1850.
6. Brzozowski A.M., Pike A.C.W., Dauter Z.et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
7. Maalouf G.J., Xu W., Smith T.F., Mohr S.C. Homology model for the ligand-binding domain of the human estrogen receptor. J. Biomol. Struc. Dyn. 15:1998;841-851.
8. Montana M.M., Muller V., Trobaugh A., Katzenellenbogen B.S. The carboxy-terminal F domain of the human estrogen receptor. role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists Mol. Endocrinol. 9:1995;814-825.
9. Tonetti D.A., Jordan V.C. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J. Steroid. Biochem. Mol. Biol. 62:1997;119-128.
10. Yao K., Lee E.S., Bentrem D.J.et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 6:2000;2028-2036.
11. Madsen M.W., Reiter B.E., Larson S.S., Briand P., Lykkesfeldt A.E. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res. 57:1997;585-589.
12. Tremblay G.B., Giguère V. Coregulators of estrogen receptor action. Crit. Rev. Eukaryotic. Gene Expression. 12:2002;1-22.
13. Clark R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., Leonessa F. Molecular and pharmacological aspects of antiestrogen resistance. J. Steroid Biochem. Mol. Biol. 76:2001;71-84.
14. Katzenellenbogen B.S., Montano M.M., Ekena K., Herman M.E., McInerney E.M., William L. McGuire Memorial Lecture. Antiestrogens. mechanisms of action and resistance in breast cancer Breast Cancer Res. Treat. 44:1997;23-38.
15. Becker M, Sommer A, Krätzschmar J, Seidel H, Pohlenz H-D, Fichtner I. Oligonucleotide chip analysis reveals distinctive gene expression patterns in Tam-sensitive and-resistant human mammary carcinoma xenografts. 14th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics", 19-22 Nov 2002, Frankfurt, Germany.
16. Vickers P.J., Dickson R.B., Shoemaker R., Cowan K.H. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol. 2:1988;886-892.
17. Zeisig R., Arndt D., Stahn R., Fichtner I. Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid. Biochim. Biophys. Acta. 1414:1998;238-248.
18. Naundorf H., Fichtner I., Elbe B.et al. Establishment and characteristics of two new human mammary carcinoma lines in nude mice with special reference to the estradiol receptor status and the importance of stroma for in vivo and in vitro growth. Breast Cancer Res. Treat. 32:1994;187-196.
19. Naundorf H., Fichtner I., Saul G.J., Haensch W., Büttner B. Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice. J. Cancer Res. Clin. Oncol. 119:1993;652-656.
20. Fichtner I., Naundorf H., Saul G.J., Zschiesche W., Zeisig R. Establishment and characterization of human xenotransplanted breast carcinoma lines. use for the screening of alkylphosphocholines (APC) Arnold W., Köpf-Maier P., Micheel B. Immunodeficient Animals: Models for Cancer Research, Vol. 51. 1996;129-133 Contrib Oncol Basel, Karger.
21. Naundorf H., Fichtner I., Büttner B., Frege J. Establishment and characterization of a new human oestradiol- and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice. J. Cancer Res. Clin. Oncol. 119:1992;35-40.
22. Naundorf H., Rewasowa E.C., Fichtner I., Büttner B., Becker M., Görlich M. Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives. Breast Cancer Res. Treat. 23:1992;87-95.